Neuro3d Completes a EUR 31.5 Million Third Round Financing

05-Jan-2005

Neuro3d, a biopharmaceutical company focused on drug discovery and development for psychiatric disorders, announced that it has raised EUR 31.5 million (USD 42.9 million) in a third round of financing from a consortium of international investors, led by Gilde Investment Management's Biotech fund and co-led by AXA Private Equity. Also participating in the round, were new investors Healthcare Private Equity LP (Scottish Widows Investment Partnership) and GIMV, and returning investors, HealthCap, Techno Venture Management Partners (TVM), Sofinnova Partners and APAX Partners.

The new funds will be used to continue the clinical development of the Company's broad pipeline of innovative drug candidates targeting psychiatric disorders, such as schizophrenia, depression and anxiety, as well as accelerate additional drug candidates into the clinic to broaden its late-stage pipeline with innovative drugs acting via new mechanism of actions. The Company's drug portfolio includes ocaperidone in Phase II trials for treatment of schizophrenia, two new antidepressants with different mechanism of actions in Phase I trials and several drug candidates in research or preclinical development.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances